Efgartigimod in refractory autoimmune myasthenia gravis
Muscle & Nerve · 2024-09 · 70 (3) · 325-332
DOI: 10.1002/mus.28184 ↗Kurz gefasst
Fachartikel in der Zeitschrift Muscle & Nerve, online erschienen am 20.06.2024. Verfasst von Linda Remijn-Nelissen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Myasthenia Gravis, Quality of Life. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Argenx (Ghent, Belgium).
Abstract (Originalsprache)
Introduction/Aims Efgartigimod, a neonatal Fc‐receptor inhibitor, has recently been approved as treatment for myasthenia gravis (MG). In this retrospective cohort study, we aimed to systematically assess short‐ and long‐term effectiveness of efgartigimod in patients with refractory MG.
Methods
Sixteen patients with refractory autoimmune acetylcholine receptor MG were treated with efgartigimod. Data were collected from January 2021 to March 2023 on Myasthenia Gravis Activities of Daily Living (MG‐ADL), Quantitative Myasthenia Gravis score (QMG), Myasthenia Gravis Composite score (MGC) and the 15‐item revised version of the Myasthenia Gravis Quality of Life questionnaire (MG‐QoL15r).
Results
A favorable outcome was seen in 56% of patients at the last measurement. Out of 16 patients, 50% were an MG‐ADL responder after the first treatment cycle. After 4 weeks, a clinically meaningful improvement compared to baseline was seen on the MG‐ADL, QMG, and MGC. There was a statistically significant improvement on the MGQoL15r from baseline to week 4. The improvement was maintained until the last measurement for the MGC and the MGQoL15r. At the last visit, all patients had discontinued 4‐weekly dosages, shifting to administration frequencies of 1, 2, or 3 weeks. Drug doses could be decreased for prednisolone ( n = 7), azathioprine ( n = 2), and intravenous immunoglobulin ( n = 9). Frequency of plasma exchange was decreased in nine patients.
Discussion
In patients with refractory MG, efgartigimod was effective for at least half of all patients. Patients required more frequent dosing compared to the ADAPT phase 3 trial. In 80% of the patients concurrent medication could be reduced or discontinued.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
ORCID-Profile: Linda Remijn-Nelissen, Martijn R Tannemaat, Yvonne J M Campman
Förderung
- Argenx (Ghent, Belgium)
Zitieren
APA
Remijn-Nelissen, L., Tannemaat, M. R., Ruiter, A. M., Campman, Y. J. M., & Verschuuren, J. J. G. M. (2024). Efgartigimod in refractory autoimmune myasthenia gravis. Muscle & Nerve, 70(3), 325-332. https://doi.org/10.1002/mus.28184
Vancouver
Remijn-Nelissen L, Tannemaat MR, Ruiter AM, Campman YJM, Verschuuren JJGM. Efgartigimod in refractory autoimmune myasthenia gravis. Muscle & Nerve. 2024;70(3):325-332. doi:10.1002/mus.28184
BibTeX
@article{RemijnNelissen2024,
author = {Remijn-Nelissen, Linda and Tannemaat, Martijn R and Ruiter, Annabel M and Campman, Yvonne J M and Verschuuren, Jan J G M},
title = {Efgartigimod in refractory autoimmune myasthenia gravis},
journal = {Muscle & Nerve},
year = {2024},
volume = {70},
number = {3},
pages = {325--332},
doi = {10.1002/mus.28184}
}
EUVIMED